New cancer immunotherapy targeting myeloid cells slows tumor growth

Checkpoint inhibitors, a type of immunotherapy, that target myeloid immune cells and slow tumor growth were discovered by a team from the Perelman School of Medicine at the University of Pennsylvania and other institutions. Reporting in Nature Cancer, the researchers showed for the first time in human cells and a mouse model that inhibiting the c-Rel molecule in myeloid cells — as opposed to lymphoid cells that today’s immunotherapies target — blocked the production of immune suppressor cells and significantly shrank tumors.